Histone deacetylase inhibitor ITF2357 (Givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma

Purpose Aberrant expression and activity of histone deacetylases (HDACs) sustain glioblastoma (GBM) onset and progression, and, therefore, HDAC inhibitors (HDACi) represent a promising class of anti-tumor agents. Here, we analyzed the effects of ITF2357 (givinostat), a pan-HDACi, in GBM models for its anti-neoplastic potential.